41 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
10 Feb 15
Notice of Extraordinary General Meeting of Shareholders
12:00am
granted to the Executive automatically upon a change in control; and
4. The Accrued Rights.
(d)Termination Upon Death or Disability.
1. In the case … of death, the Executive’s legal representative shall be entitled to the Base Salary through the last day of the month in which the death occurred, pro
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
27 Oct 15
Current report (foreign)
12:00am
are frequently the cause of death.
The HOPEMD study was designed as a proof–of-concept open-label clinical study in 74 patients for 24 weeks, following … of protein aggregations, and promoting their clearance from cells through autophagy, thus preventing muscle cell death.
About Oculopharyngeal Muscular
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 May 22
Report of Foreign Private Issuer
8:04am
, as ovarian cancer is currently the fifth leading cause of cancer death among women.
Murine ovarian cancer study results:
Substantial survival effect … is currently the fifth leading cause of cancer death among women. Stand-alone therapy with PD1 checkpoint inhibitors, which are designed to treat cancer
6-K
EX-99.2
rfq55ah7lt6kfeuv
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
424B5
n0s9ai
18 Mar 16
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
5l12jh 6u
22 Sep 14
Bio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal
12:00am
6-K
EX-99.1
7qgt43r5m1
8 Jan 15
Current report (foreign)
12:00am
6-K
lfziv0 l0
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.1
82p7fl
19 Aug 19
Report of Foreign Private Issuer
7:31am
6-K
EX-99.1
tbfuii
17 Sep 14
BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3HOPEMD Study in OPMD
12:00am
6-K
EX-99.1
okv lcsqsi2r42cd1i
24 Oct 16
Bioblast Announces Results of Trehalose Clinical Study
12:00am
6-K
EX-99.1
iavy5y9e2l7hcy2
4 Nov 19
Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
7:30am
6-K
EX-99.1
h6hvx2rw a8kr3s2
18 Mar 20
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
8:26am
424B4
z81r3bah xgsp
31 Jul 14
Prospectus supplement with pricing info
12:00am
6-K
EX-99.1
nbvhqrfcins3
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
F-1/A
0dy9l 018
8 Jul 14
Registration statement (foreign) (amended)
12:00am